SUBSCRIBE: Print / eNewsletter
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer.
Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics.
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor.
Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
